Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: The randomized, controlled ThromboVIT trial

Inflammatory Bowel Diseases

Volumn 19, Issue 8, 2013, Pages 1609-1616

  Kulnigg Dabsch, Stefanie ^a   Schmid, Werner ^b   Howaldt, Stefanie ^c   Stein, Jürgen ^d   Mickisch, Oliver ^e   Waldhör, Thomas ^f   Evstatiev, Rayko ^a,b   Kamali, Houman ^g   Volf, Ivo ^b   Gasche, Christoph ^a,b,h,i  

^a Division of Gastroenterology and Hepatology   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c IBD Centre North   (Germany)

^d Katharina Kasper Hospital   (Germany)

^e Gastroenterol Schwerpunktpraxis   (Germany)

^f Department of Epidemiology ^*  (Austria)

^g Vifor (International) Inc   (Switzerland)

^h Loha for Life Centre of Excellence for Iron Deficiency   (Austria)

ⁱ UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ferric carboxymaltose; Inflammatory bowel disease; Intravenous iron therapy; Iron deficiency; Secondary thrombocytosis

Indexed keywords

ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; GROWTH FACTOR; HEMOGLOBIN; PADGEM PROTEIN; PLACEBO;

ACNE; ADULT; ARTICLE; CELL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG SAFETY; ENTERITIS; ERYTHEMA; FEMALE; FISTULA; HEART FAILURE; HUMAN; IRON DEFICIENCY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SINGLE BLIND PROCEDURE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOSIS;

ADOLESCENT; ADULT; ANEMIA, IRON-DEFICIENCY; ERYTHROPOIETIN; FEMALE; FERRIC COMPOUNDS; HEPCIDINS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MALTOSE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET COUNT; PROGNOSIS; PROSPECTIVE STUDIES; THROMBOCYTOSIS; YOUNG ADULT;

EID: 84884551031     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318281f4db     Document Type: Article

References (27)

1. Beer PA. The pathogenesis of essential thrombocythemia. Curr Opin Hematol. 2011;18:323-329.
2. Schafer AI. Thrombocytosis and thrombocythemia. Blood Rev. 2001;15: 159-166.
3. Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104:2822-2829.
4. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost. 2010;8: 114-120.
5. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004;2:2156-2161.
6. Ceresa IF, Noris P, Ambaglio C, et al. Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. Platelets. 2007; 18: 579-582.
7. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
8. Danese S, de la Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol. 2004;99:938-945.
9. Danese S, Scaldaferri F, Papa A, et al. Platelets: new players in the mucosal scenario of inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2004;8:193-198.
10. Harries AD, Fitzsimons E, Fifield R, et al. Platelet count: a simple measure of activity in Crohn's disease. Br Med J (Clin Res Ed). 1983; 286:1476.
11. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010;139:779-787.
12. Danese S, Fiocchi C. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol. 2005;25:103-121.
13. Kulnigg-Dabsch S, Evstatiev R, Dejaco C, et al. Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS One. 2012;7:e34520.
14. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
15. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96: 804-810.
16. Bansal SS, Abbate V, Bomford A, et al. Quantitation of hepcidin in serum using ultra-high-pressure liquid chromatography and a linear ion trap mass spectrometer. Rapid Commun Mass Spectrom. 2010;24: 1251-1259.
17. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927-929.
18. Walkowiak B, Kesy A, Michalec L. Microplate reader-a convenient tool in studies of blood coagulation. Thromb Res. 1997;87:95-103.
19. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol. 2011;106: 713-718.
20. Danese S, Sans M, Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut. 2004;53:1035-1043.
21. Linden MD, Jackson DE. Platelets: pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol. 2010;42:1762-1766.
22. McMorran BJ, Marshall VM, de GC, et al. Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science. 2009;323: 797-800.
23. Suzuki K, Sugimura K, Hasegawa K, et al. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol. 2001;36: 1301-1306.
24. Lordier L, Jalil A, Aurade F, et al. Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood. 2008;112:3164-3174.
25. Mattia G, Vulcano F, Milazzo L, et al. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood. 2002;99: 888-897.
26. Choi SI, Simone JV. Platelet production in experimental iron deficiency anemia. Blood. 1973;42:219-228.
27. Nurtjahja-Tjendraputra E, Fu D, Phang JM, et al. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood. 2007;109:4045-4054.